Udenafil for the treatment of erectile dysfunction

References

• [No authors listed]Consensus development conference statement. Impotence. December 7–9, 1992Int J Impot Res1993541812848173631
   PubMedGoogle Scholar
• ShamloulRGhanemHErectile dysfunctionLancet2013381986115316523040455
   PubMed Web of Science ®Google Scholar
• KubinMWagnerGFugl-MeyerAREpidemiology of erectile dysfunctionInt J Impot Res2003151637112605242
   PubMed Web of Science ®Google Scholar
• KupelianVShabsighRAraujoABO’DonnellABMcKinlayJBErectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging StudyJ Urol2006176122222616753405
   PubMed Web of Science ®Google Scholar
• McVaryKTErectile dysfunction and lower urinary tract symptoms secondary to BPHEur Urol200547683884515925081
   PubMed Web of Science ®Google Scholar
• RosenRAltweinJBoylePLower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)Eur Urol200344663764914644114
   PubMed Web of Science ®Google Scholar
• BillupsKLSexual dysfunction and cardiovascular disease: integrative concepts and strategiesAm J Cardiol20059612B57M61M
   PubMed Web of Science ®Google Scholar
• McVaryKTCarrierSWessellsHSubcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North AmericaSmoking and erectile dysfunction: evidence based analysisJ Urol200116651624163211586190
   PubMed Web of Science ®Google Scholar
• BrownJSWessellsHChancellorMBUrologic complications of diabetesDiabetes Care200528117718515616253
   PubMed Web of Science ®Google Scholar
• McVaryKTClinical practice. Erectile dysfunctionN Engl J Med2007357242472248118077811
   PubMedGoogle Scholar
• KapurVChienCVFuessJESchwarzERThe relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular diseaseRev Cardiovasc Med20089318719518953278
   PubMed Web of Science ®Google Scholar
• MinerMMErectile dysfunction and the “window of curability”: a harbinger of cardiovascular eventsMayo Clin Proc200984210210419181641
   PubMed Web of Science ®Google Scholar
• ShabsighRShahMSandMErectile dysfunction and men’s health: developing a comorbidity risk calculatorJ Sex Med2008551237124318439154
   PubMed Web of Science ®Google Scholar
• MontorsiPRavagnaniPMGalliSAssociation between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trialEur Heart J200627222632263916854949
   PubMed Web of Science ®Google Scholar
• HodgesLDKirbyMSolankiJO’DonnellJBrodieDAThe temporal relationship between erectile dysfunction and cardiovascular diseaseInt J Clin Pract200761122019202517997808
   PubMed Web of Science ®Google Scholar
• WessellsHJoyceGFWiseMWiltTJErectile dysfunctionJ Urol200717751675168117437781
   PubMed Web of Science ®Google Scholar
• MontagueDJarowJBroderickGErectile Dysfunction Guideline Update PanelChapter 1: The management of erectile dysfunction: an AUA updateJ Urol2005174123023915947645
   PubMed Web of Science ®Google Scholar
• MontorsiFAdaikanGBecherESummary of the recommendations on sexual dysfunctions in menJ Sex Med20107113572358821040491
   PubMed Web of Science ®Google Scholar
• BruzzichesRFrancomanoDGareriPLenziAAversaAAn update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitorsExpert Opin Pharmacother201314101333134423675780
   PubMed Web of Science ®Google Scholar
• BellASPalmerMJNovel phosphodiesterase type 5 modulators: a patent survey (2008–2010)Expert Opin Ther Pat201121101631164121905762
   PubMed Web of Science ®Google Scholar
• YuanJZhangRYangZComparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysisEur Urol201363590291223395275
   PubMed Web of Science ®Google Scholar
• GlinaSToscanoIGomatzkyCEfficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trialJ Sex Med20096255355719040623
   PubMed Web of Science ®Google Scholar
• GlinaSFonsecaGNBerteroEBEfficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trialJ Sex Med2010751928193620214718
   PubMed Web of Science ®Google Scholar
• HatzimouratidisKHatzichristouDGLooking to the future for erectile dysfunction therapiesDrugs200868223125018197727
   PubMed Web of Science ®Google Scholar
• PalitVEardleyIAn update on new oral PDE5 inhibitors for the treatment of erectile dysfunctionNat Rev Urol201071160360921068761
   PubMed Web of Science ®Google Scholar
• DohHShinCYSonMMechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159Arch Pharm Res200225687387812510841
   PubMed Web of Science ®Google Scholar
• PaickJSKimSWYangDYThe efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunctionJ Sex Med20085494695318221288
   PubMed Web of Science ®Google Scholar
• ParkHJParkJKParkKMinKParkNCEfficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trialJ Sex Med2010762209221620412426
   PubMed Web of Science ®Google Scholar
• MoonDGYangDYLeeCHA therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitusJ Sex Med2011872048206121554549
   PubMed Web of Science ®Google Scholar
• ChungBHLeeJYLeeSHYooSJLeeSWOhCYSafety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTSInt J Impot Res200921212212819194451
   PubMed Web of Science ®Google Scholar
• ZhaoCKimSWYangDYEfficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trialEur Urol201160238038721458153
   PubMed Web of Science ®Google Scholar
• PaickJSKimSWParkYKThe efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agentsJ Sex Med20096113166317619694927
   PubMed Web of Science ®Google Scholar
• OrtaçMÇayanSÇalis¸kanMKEfficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled studyAndrology20131454955523785019
   PubMed Web of Science ®Google Scholar
• CorbinJDFrancisSHPharmacology of phosphodiesterase-5 inhibitorsInt J Clin Pract200256645345912166544
   PubMed Web of Science ®Google Scholar
• LueTFErectile dysfunctionN Engl J Med2000342241802181310853004
   PubMed Web of Science ®Google Scholar
• KimNNPhosphodiesterase type 5 inhibitors: a biochemical and clinical correlation surveyInt J Impot Res200315Suppl 5S13S1914551572
   PubMedGoogle Scholar
• KouvelasDGoulasAPapazisisGSardeliCPourzitakiCPDE5 inhibitors: in vitro and in vivo pharmacological profileCurr Pharm Des200915303464347519860692
   PubMed Web of Science ®Google Scholar
• KimBHLimHSChungJYSafety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjectsBr J Clin Pharmacol200865684885418318773
   PubMed Web of Science ®Google Scholar
• ShimHJKimYCParkKJPharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effectsJ Pharm Sci200392112185219514603504
   PubMed Web of Science ®Google Scholar
• WalkerDKAcklandMJJamesGCPharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and manXenobiotica199929329731010219969
   PubMed Web of Science ®Google Scholar
• ShimHJKimYCLeeJHInterspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokineticsBiopharm Drug Dispos200526726927715991256
   PubMed Web of Science ®Google Scholar
• KimTEKimBHKimJREffect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunctionBr J Clin Pharmacol2009681434619660002
   PubMed Web of Science ®Google Scholar
• WallisRMCorbinJDFrancisSHEllisPTissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitroAm J Cardiol1999835A3C12C
   PubMed Web of Science ®Google Scholar
• FrancisSHTurkoIVCorbinJDCyclic nucleotide phosphodiesterases: relating structure and functionProg Nucleic Acid Res Mol Biol20016515211008484
   PubMed Web of Science ®Google Scholar
• BischoffEPotency, selectivity, and consequences of nonselectivity of PDE inhibitionInt J Impot Res200416Suppl 1S11S1415224129
   PubMed Web of Science ®Google Scholar
• GresserUGleiterCHErectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil – review of the literatureEur J Med Res200271043544612435622
   PubMed Web of Science ®Google Scholar
• KuHYAhnHJSeoKAThe contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafilDrug Metab Dispos200836698699018308836
   PubMed Web of Science ®Google Scholar
• JiHYLeeHWKimHHRole of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenicXenobiotica20043411–1297398215801542
   PubMed Web of Science ®Google Scholar
• KimJKimSJJiHYSimultaneous determination of a new phosphodiesterase-5 inhibitor DA-8159 and its active metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometryChromatographia2003577–8447450
   Web of Science ®Google Scholar
• AmakyeDWardJBrysonSHanKDA-8159-phase I studies to investigate the safety and pharmacokinetics in healthy male Caucasian subjectsClin Pharmacol Ther20047586
   Web of Science ®Google Scholar
• HatzichristouDAmarEEardleyIGuidelines on male sexual dysfunction: erectile dysfunction and premature ejaculationEur Urol201057580481420189712
   PubMed Web of Science ®Google Scholar
• OhTYKangKKAhnBOYooMKimWBErectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159Arch Pharm Res200023547147611059826
   PubMed Web of Science ®Google Scholar
• SalemEAKendirciMHellstromWJUdenafil, a long-acting PDE5 inhibitor for erectile dysfunctionCurr Opin Investig Drugs200677661669
   PubMedGoogle Scholar
• DingHDuWWangHEfficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trialsUrology201280113413922497982
   PubMed Web of Science ®Google Scholar
• ThorveVSKshirsagarADVyawahareNSJoshiVSIngaleKGMohiteRJDiabetes-induced erectile dysfunction: epidemiology, pathophysiology and managementJ Diabetes Complications201125212913620462773
   PubMed Web of Science ®Google Scholar
• KangKKChoiSMAhnGJKwonJWKimWBThe effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbitsUrol Res200432210711115024530
   PubMedGoogle Scholar
• AhnGJSohnYSKangKKThe effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic ratsInt J Impot Res200517213414115578039
   PubMed Web of Science ®Google Scholar
• AhnGJYuJYChoiSMChronic administration of phosphodi-esterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetesInt J Androl200528526026616128985
   PubMedGoogle Scholar
• AhnGJChungHKLeeCHKangKKAhnBOIncreased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesisAsian J Androl200911443544219465935
   PubMed Web of Science ®Google Scholar
• ChoSYParkKPaickJSKimSWChange of erectile function and responsiveness to phosphodiesterase type 5 inhibitors at different stages of streptozotocin-induced diabetes in ratsJ Sex Med2011851352136121054802
   PubMed Web of Science ®Google Scholar
• Martínez-SalamancaJICarballidoJEardleyIPhosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidenceEur Urol201160352753521684677
   PubMed Web of Science ®Google Scholar
• GacciMCoronaGSalviMA systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasiaEur Urol2012615994100322405510
   PubMed Web of Science ®Google Scholar
• Behr-RousselDGornyDMevelKChronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxisEur Urol2005471879115582254
   PubMed Web of Science ®Google Scholar
• PorstHGiulianoFGlinaSEvaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trialEur Urol200650235135916766116
   PubMed Web of Science ®Google Scholar
• PorstHRajferJCasabéALong-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunctionJ Sex Med2008592160216918557812
   PubMed Web of Science ®Google Scholar
• BellaAJDeyoungLXAl-NumiMBrockGBDaily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indicationsEur Urol2007524990100517646047
   PubMed Web of Science ®Google Scholar
• MinerMBillupsKLErectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statinsJ Sex Med2008551066107818331271
   PubMed Web of Science ®Google Scholar
• LewisRWSadovskyREardleyIThe efficacy of tadalafil in clinical populationsJ Sex Med20052451753116422847
   PubMed Web of Science ®Google Scholar
• MinerMGildermanLBailenJVardenafil in men with stable statin therapy and dyslipidemiaJ Sex Med2008561455146718373526
   PubMed Web of Science ®Google Scholar
• KangKKYuJYYooMKwonJWThe effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunctionInt J Impot Res200517540941615920460
   PubMed Web of Science ®Google Scholar
• HatzimouratidisKBurnettALHatzichristouDMcCulloughARMontorsiFMulhallJPPhosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical applicationEur Urol200955233434718986755
   PubMed Web of Science ®Google Scholar
• LeeCHKimHSGooMJChronic administration of udenafil, a selective phosphodiesterase type 5 inhibitor, promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injuryJ Sex Med2011851330134021366883
   PubMed Web of Science ®Google Scholar
• LeeCHShinJHAhnGJKangKKAhnBOYooMUdenafil enhances the recovery of erectile function and ameliorates the pathophysiological consequences of cavernous nerve resectionJ Sex Med2010772564257120524975
   PubMed Web of Science ®Google Scholar
• KimIKimDAnterior ischemic optic neuropathy associated with udenafilKorean J Ophthalmol201226323523822670084
   PubMedGoogle Scholar
• BaeEKAhnJHParkJJNonaneurysmal subarachnoid hemorrhage after udenafil intakeJ Stroke Cerebrovasc Dis Epub522013
   Google Scholar
• KimMGKimJRKimBHThe effect of udenafil on the hemodynamics of healthy male volunteers administered tamsulosinCurr Med Res Opin201329668569323557068
   PubMed Web of Science ®Google Scholar
• BernerMMKristonLHarmsAEfficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populationsInt J Impot Res200618322923516239897
   PubMed Web of Science ®Google Scholar
• VardiMNiniAPhosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitusCochrane Database Syst Rev20071CD00218717253475
   PubMed Web of Science ®Google Scholar
• Sáenz de TejadaIAnglinGKnightJREmmickJTEffects of tadalafil on erectile dysfunction in men with diabetesDiabetes Care200225122159216412453954
   PubMed Web of Science ®Google Scholar
• GoldsteinIYoungJMFischerJBangerterKSegersonTTaylorTVardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose studyDiabetes Care200326377778312610037
   PubMed Web of Science ®Google Scholar
• BlondeLSildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trialsCurr Med Res Opin200622112111212017076971
   PubMed Web of Science ®Google Scholar
• KlonerRASadovskyRJohnsonEGMoDAhujaSEfficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapyInt J Impot Res200517545045416015377
   PubMed Web of Science ®Google Scholar
• ShabsighRDuvalSShahMReganTSJuhaszMVeltryLGEfficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial dataCurr Med Res Opin200723102453246017727740
   PubMed Web of Science ®Google Scholar
• KlonerRABrownMPrisantLMCollinsMEffect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study GroupAm J Hypertens2001141707311206684
   PubMed Web of Science ®Google Scholar
• van AhlenHWahleKKupperWYassinAReblinTNeureitherMSafety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensivesJ Sex Med20052685686416422810
   PubMed Web of Science ®Google Scholar
• Rubio-AuriolesEPorstHKimEDA randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs tadalafil or sildenafil on-demand in men with erectile dysfunctionJ Sex Med2012951418142922429760
   PubMed Web of Science ®Google Scholar
• RajferJAliottaPJSteidleCPFitchWP3rdZhaoYYuATadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the USInt J Impot Res20071919510316871272
   PubMed Web of Science ®Google Scholar
• GiulianoFVicautEJeanpetitYImpact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse intervalProg Urol20081853654218760744
   PubMed Web of Science ®Google Scholar
• EardleyIEllisPBoolellMWulffMOnset and duration of action of sildenafil for the treatment of erectile dysfunctionBr J Clin Pharmacol200253Suppl 161S65S11879261
   PubMed Web of Science ®Google Scholar
• ZinnerNDo food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled studyJ Sex Med2007413714417233779
   PubMed Web of Science ®Google Scholar
• MoncadaIJaraJSubiráDCastañoIHernándezCEfficacy of sildenafil citrate at 12 hours after dosing: Re-exploring the therapeutic windowEur Urol20044635736015306108
   PubMed Web of Science ®Google Scholar
• PorstHSharlipIDHatzichristouDExtended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled studyEur Urol2006501086109516820261
   PubMed Web of Science ®Google Scholar
• MeulemanEJReview of tadalafil in the treatment of erectile dysfunctionExpert Opin Pharmacother200342049205614596658
   PubMed Web of Science ®Google Scholar
• CoronaGMondainiNUngarARazzoliERossiAFuscoFPhosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patientJ Sex Med201183418343221995676
   PubMed Web of Science ®Google Scholar
• MironeVFuscoFRossiASicuteriRMontorsiFTadalafil and vardenafil vs sildenafil: a review of patient-preference studiesBJU Int20091031212121719154480
   PubMed Web of Science ®Google Scholar
• Warner ChilcottTreatment of Erectile Dysfunction II Available from: http://clinicaltrials.gov/ct2/show/NCT01037218. NLM identifier:NCT01037218Accessed November 18, 2013
   Google Scholar
• Warner ChilcottTreatment of Erectile Dysfunction - Long Term Safety and Efficacy Available from: http://clinicaltrials.gov/ct2/show/NCT01065012. NLM identifier:NCT01065012Accessed November 18, 2013
   Google Scholar